HUE033306T2 - Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog - Google Patents

Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog Download PDF

Info

Publication number
HUE033306T2
HUE033306T2 HUE06712292A HUE06712292A HUE033306T2 HU E033306 T2 HUE033306 T2 HU E033306T2 HU E06712292 A HUE06712292 A HU E06712292A HU E06712292 A HUE06712292 A HU E06712292A HU E033306 T2 HUE033306 T2 HU E033306T2
Authority
HU
Hungary
Prior art keywords
cancer
drug
dose
day
patient
Prior art date
Application number
HUE06712292A
Other languages
English (en)
Hungarian (hu)
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE033306(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of HUE033306T2 publication Critical patent/HUE033306T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE06712292A 2005-01-26 2006-01-25 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog HUE033306T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06

Publications (1)

Publication Number Publication Date
HUE033306T2 true HUE033306T2 (hu) 2017-11-28

Family

ID=36740357

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE06712292A HUE033306T2 (hu) 2005-01-26 2006-01-25 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog
HUS1700032C HUS1700032I1 (hu) 2005-01-26 2017-08-01 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1700032C HUS1700032I1 (hu) 2005-01-26 2017-08-01 Alfa, alfa, alfa-trifluortimidint és timidin-foszforiláz inhibitort tartalmazó rákellenes drog

Country Status (20)

Country Link
EP (1) EP1849470B2 (enExample)
JP (1) JP5576591B2 (enExample)
KR (1) KR101468216B1 (enExample)
AU (1) AU2006209547C1 (enExample)
BE (1) BE2017C028I2 (enExample)
CA (1) CA2594713A1 (enExample)
CY (2) CY2017029I2 (enExample)
DK (1) DK1849470T4 (enExample)
ES (1) ES2630002T5 (enExample)
FI (1) FI1849470T4 (enExample)
FR (1) FR17C1028I2 (enExample)
HU (2) HUE033306T2 (enExample)
LT (2) LT1849470T (enExample)
LU (1) LUC00036I2 (enExample)
NL (1) NL300889I2 (enExample)
PL (1) PL1849470T5 (enExample)
PT (1) PT1849470T (enExample)
SI (1) SI1849470T2 (enExample)
TW (1) TWI362265B (enExample)
WO (1) WO2006080327A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
PL2746404T3 (pl) 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i sposób przewidywania efektu terapeutycznego u pacjentów z rakiem jelita grubego z mutacją kras
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
US9616081B2 (en) * 2013-03-27 2017-04-11 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
UA114840C2 (uk) * 2013-03-27 2017-08-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний агент, який включає гідрат гідрохлориду іринотекану
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014316030C1 (en) 2013-09-06 2024-08-15 Les Laboratoires Servier Antitumor agent and antitumor effect enhancer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3693019A1 (en) 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
KR102412690B1 (ko) 2016-02-05 2022-06-23 다이호야쿠힌고교 가부시키가이샤 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (ja) 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
EP0884051B1 (en) * 1996-09-24 2004-12-15 Taiho Pharmaceutical Company Limited Cancerous metastasis inhibitors containing uracil derivatives
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Also Published As

Publication number Publication date
RU2007132181A (ru) 2009-03-10
JPWO2006080327A1 (ja) 2008-06-19
LUC00036I2 (enExample) 2017-12-01
FR17C1028I2 (fr) 2018-11-02
LUC00036I1 (enExample) 2017-10-02
PL1849470T3 (pl) 2017-11-30
ES2630002T5 (es) 2024-09-19
DK1849470T4 (en) 2024-04-02
BE2017C028I2 (enExample) 2025-09-10
CY2017029I1 (el) 2018-02-14
JP5576591B2 (ja) 2014-08-20
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
ES2630002T3 (es) 2017-08-17
AU2006209547A1 (en) 2006-08-03
TW200637562A (en) 2006-11-01
CY2017029I2 (el) 2018-02-14
SI1849470T2 (sl) 2024-05-31
TWI362265B (en) 2012-04-21
SI1849470T1 (sl) 2017-10-30
PL1849470T5 (pl) 2024-06-10
NL300889I2 (nl) 2018-01-16
AU2006209547B2 (en) 2011-05-26
FI1849470T4 (fi) 2024-03-22
AU2006209547C1 (en) 2022-04-07
EP1849470A1 (en) 2007-10-31
EP1849470B2 (en) 2024-03-20
HUS1700032I1 (hu) 2017-09-28
NL300889I1 (nl) 2017-08-14
CA2594713A1 (en) 2006-08-03
PT1849470T (pt) 2017-09-22
LTPA2017024I1 (lt) 2017-08-10
CY1119393T1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
WO2006080327A1 (ja) 2006-08-03
KR101468216B1 (ko) 2014-12-03
LT1849470T (lt) 2017-07-25
FR17C1028I1 (enExample) 2017-09-29
KR20070104559A (ko) 2007-10-26
DK1849470T3 (en) 2017-08-14
RU2394581C2 (ru) 2010-07-20

Similar Documents

Publication Publication Date Title
EP1849470B2 (en) Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
KR101848131B1 (ko) 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
US20070232592A1 (en) Therapeutic Compositions Containing at Least one Pyrrolobenzodiazepine Derivative and Fludarabine
WO1992021345A1 (en) Composition, method and kit for potentiating antitumor activity and for curing tumor
JP2000273044A (ja) 副作用軽減剤
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CN107137417B (zh) 一种用于治疗恶病质的药物组合物及其应用
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
TWI615145B (zh) 含伊立替康鹽酸鹽水合物之抗腫瘤劑
JP6895688B2 (ja) 血液がんの新規治療法及び新規治療剤
ES2896051T3 (es) Fármaco antitumoral que contiene un complejo de platino antitumoral y un potenciador del efecto antitumoral
WO2018121669A1 (zh) 一种用于治疗癌症的药物组合物及其应用
US11957701B2 (en) Therapy and new therapeutic agent for blood cancer
TW202140018A (zh) 含有尿嘧啶衍生物化合物之抗腫瘤效果增強劑
TWI827864B (zh) 血液癌之新穎治療法及新穎治療劑
JP2015199678A (ja) ラパチニブトシル酸塩水和物を含有する抗腫瘍剤及び抗腫瘍効果増強剤
CN115581703A (zh) 复方吉西他滨组合物及应用
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
TW201143769A (en) Anti-tumor agent combined with kinase inhibitor